ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos 10.3892/etm.2015.2399 ETM-0-0-2399 Articles Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid KINDELLDANIEL GLENN 1 KECKRICK WAYNE 1 JANKUNJERZY 1 3 Urology Research Center, Department of Urology, University of Toledo, Health Science Campus, Toledo, OH 43614, USA Protein Research Chair, Department of Biochemistry, College of Sciences, King Saud University, Riyadh 11451, Kingdom of Saudi Arabia Department of Clinical Nutrition, Medical University of Gdańsk, Gdańsk, Pomerania 80-211, Poland Correspondence to: Professor Jerzy Jankun, Urology Research Center, Department of Urology, University of Toledo, Health Science Campus, 3,000 Arlington Avenue, Toledo, OH 43614, USA, E-mail: jerzy.jankun@utoledo.edu 06 2015 01 04 2015 9 6 2339 2343 20082014 17112014 Copyright © 2015, Spandidos Publications 2015

Plasminogen activator inhibitor (PAI)-1 is a serpin glycoprotein that can stabilize blood clots by inhibiting fibrinolysis. However, wild-type PAI-1 has the disadvantage of a short half-life of ∼2 h. A very long half-life (VLHL) PAI-1 mutant was developed previously with an active-form half-life of >700 h, making it a possible candidate for use in hemorrhagic therapy. Current treatments for mitigating hemorrhage, other than inducers of blood clotting, are limited to lysine analog antifibrinolytics, including 6-aminocaproic acid and tranexamic acid. VLHL PAI-1 has been previously demonstrated to limit bleeding; however, the efficacy of this protein compared with lysine analog antifibrinolytics has not been investigated. The aim of the current study was to compare the clot stabilizing properties of the novel antifibrinolytic VLHL PAI-1 with those of 6-aminocaproic acid in reference plasma. Using thromboelastographic analysis, VLHL PAI-1 exhibited an IC50 (half maximal inhibitory concentration) of 8.8×10−8 mol/l, while 6-aminocaproic acid showed an IC50 of 1.6×10−4 mol/l. However, at doses of >9.0×10−7 mol/l, VLHL PAI-1 exhibited a delay in the onset of clot formation, which may be attributed to thrombin inhibition by excess PAI-1. The inhibition of tissue plasminogen activator by VLHL PAI-1 demonstrated improved efficacy over 6-aminocaproic acid in mitigating hemorrhage. In addition, patients with a PAI-1 deficiency, which causes blood clots to lyse rapidly resulting in profuse bleeding, may benefit from the application of VLHL PAI-1 as an antihemorrhagic therapy.

 plasminogen activator inhibitor-1 6-aminocaproic acid thromboelastography blood clotting Introduction

Coagulation, the formation of a clot, is an essential process in the maintenance of homeostasis under normal conditions and during traumatic events. Numerous agents are used to initiate clotting and prevent uncontrolled bleeding. However, only a few agents, with limited efficacy, are used in clinical practice to protect formed clots against premature lysis (1,2). The crosslinked polymer, fibrin, is dissolved into fibrin degradation products by plasmin. Thus, preventing the activation of plasmin is a potential target for antihemorrhage therapy. Plasmin, the primary fibrinolytic protease responsible for fibrin solvation, is formed by proteolytic cleavage of the zymogen plasminogen by tissue plasminogen activator (tPA) or urokinase plasminogen activator (uPA) (3–6). Vascular endothelial cells synthesize tPA, and tPA-mediated plasminogen activation is accelerated in the presence of fibrin (5,6).

An appropriate level of plasminogen activation is maintained through the competing activity of plasminogen activators and plasminogen activator inhibitors (PAIs). The most relevant PAI in clot formation is PAI-1 (7), which is the quickest acting and most physiologically specific inhibitor of tPA (5,8). The three conformational states of PAI-1 are latent (inactive), active and reactive-center-cleaved (plasminogen-activator complexed) (9). The active form of PAI-1 is rapidly converted (half-life, 1–2 h) into the latent form at physiological temperatures and pH (6,7,10). This relatively short half-life makes it difficult to use PAI-1 therapeutically as a clot protector. However, a previous study described a novel, genetically-engineered, antifibrinolytic PAI-1 with a significantly longer half-life (>700 h) compared with the wild-type (11).

The aim of the present study was to compare the antifibrinolytic activity of this very long half-life PAI-1 (VLHL PAI-1) with 6-aminocaproic acid (also known as ε-aminocaproic acid or Amicar) in the presence of tPA by establishing dose-response curves and determining the IC50 (half maximal inhibitory concentration) using thromboelastography (TEG).

 Materials and methods <sec> <title>Clot-protecting activity assay

A clot-protecting activity assay was performed using a TEG® 5000 Thrombelastograph® (Haemonetics Corporation, Braintree, MA, USA). The thrombelastograph measured coagulation with a pin attached to a torsion wire suspended in a cup holding a plasma sample. The TEG® was calibrated with plasma controls Level I (reading of TEG parameters within: R, 0–4 min; Angle, 75–87°; MA, 42–63 mm; K, 0–2 min) and II (reading of TEG parameters within: R, 1–5 min; Angle, 60–80°; MA, 26–41 mm; K, 0–6 min) (Haemoscope Corporation, Neils, IL, USA). Reference plasma (Coagulation Specialty Assayed Reference Plasma; Helena Laboratories Corporation, Beaumont, TX, USA) was reconstituted in 1 ml distilled water and mixed with 20 µl kaolin (Haemonetics Corporation). In trials where tPA was utilized, 20 µl tPA (2 mg/ml; Molecular Innovations, Novi, MI, USA) was added directly to the plasma. Next, 320 µl plasma/kaolin solution was added to the TEG® cup containing 20 µl calcium chloride (0.2 M).

 Trials

Each trial consisted of two samples running simultaneously, containing the same plasma/kaolin solution. The control TEG® cup received 10 µl distilled water and the experimental TEG® cup received the appropriate combination of VLHL PAI-1, 6-aminocaproic acid (Sigma-Aldrich, St. Louis, MI, USA) and distilled water. The 6-aminocaproic acid was reconstituted with distilled water. Expression and purification of VLHL PAI-1 was conducted as described in a previous study (6). Serial dilutions of VLHL PAI-1 were performed with saline (0.15 M) and each trial ran for 45 min at 37°C.

 Statistical analysis

Statistical analysis was performed using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA), and differences between the groups were analyzed by two-way analysis of variance. The data were presented as the mean ± standard deviation, and P<0.05 was considered to indicate a statistically significant difference. Graph visualization was performed using Origin 8 software (OriginLab, Northampton, MA, USA).

 Results <sec> <title>Clotting parameters for the reference and tPA-treated plasma

Selected clotting parameters for the control and various doses of 6-aminocaproic acid and VLHL PAI-1 are shown in Table I and Figs. 1 and 2. Control samples consisted of reference and tPA-treated plasma, with tPA included to mimic clot lysis. Reference and tPA-treated plasma exhibited similar average control values, with the exception of a lower clot strength (G), maximum amplitude (MA) and rate of clot lysis after 30 min (LY30) in the tPA-treated plasma due to tPA-induced clot lysis, which is consistent with previous studies (12–16). The MA was lower, as reference plasma lacks platelets that strengthen the blood clot (3,17–19). There are no normal values of TEG parameters for reference plasma in the literature. However, normal blood samples are considered to have a reaction time (R) of 2–8 min, a 2–4-min period between the reaction onset and the formation of a 20-mm clot, an MA of 51–69 mm and a LY30 value of 0–8% (12).

 6-aminocaproic acid treatment decreases the incidence rate of clot lysis after 30 min

Doses of 6-aminocaproic acid that were ≥18 µg generated LY30 values of ≤5%, indicating that the formed fibrin clot was almost entirely intact. Serial dilutions of ≤9 µg yielded significantly different (P<0.01) LY30 values, ranging between 26.7 and 87.4%, as compared with the controls (Fig. 1). The IC50 of 6-aminocaproic acid was 6.5 µg or 1.6×10−4 mol/l when expressed as a concentration. No dosage of 6-aminocaproic acid produced a delay in clot formation (Fig. 1). The maximum G achieved by 6-aminocaproic acid was 1.8 kdyn/cm2.

 VLHL PAI-1 treatment decreases incidence rate of clot lysis after 30 min

At doses of ≥3.125 µg VLHL PAI-1, tPA action was completely inhibited, generating LY30 values of 0%. Doses of ≤0.78 µg generated statistically significant differences (P<0.01) in LY30 values, which ranged between 32.1 and 92.2%, as compared with the controls. The IC50 of VLHL PAI-1 was 0.68 µg or 8.8×10−8 mol/l when expressed as a concentration (Fig. 1). In addition, VLHL PAI-1 doses of ≥12.5 µg produced a statistically significant (P<0.01) increase in R, as compared with the controls (Fig. 2). VLHL PAI-1 achieved a maximum G of 2.3 kdyn/cm2.

 Discussion

There are three conformational states of PAI-1, including latent (inactive), active and reactive-center-cleaved (plasminogen-activator-complex) (9,10). The active form of PAI-1 is rapidly converted (half-life, 1–2 h) into the latent form at a physiological temperature and pH (7,9,10,20). The reactive center loop of PAI-1, which contains the active site, is connected to β-sheet C at the C-terminal and β-sheet A at the N terminal (9). In the latent form, the reactive center loop is inserted into β-sheet A (central β-sheet), thereby eliminating the possibility of proteinase interaction with the reactive peptide bond (P1-P1) of tPA or uPA, and PAI-1 becomes inactive (7,9,10). Thus, only active PAI-1 can be used as a clot protector. We previously developed a VLHL PAI-1 mutant that remained active for >700 h, and despite the two cysteine mutations, the VLHL PAI-1 structure was found to be almost identical to wild-type PAI-1 (10,11,21,22). The long half-life of VLHL PAI-1 has enabled this protein to become a potential therapeutic agent for the mitigation of bleeding.

None of the current antifibrinolytics, including aprotinin, 6-aminocaproic acid and tranexamic acid (TXA), are without side effects, warranting the development of new hemostatic agents (14). TXA has been shown to have a statistical association with seizure induction, possibly due to cerebral ischemia caused by a decrease in regional or global cerebral blood flow (20). Aprotinin functions via the same mechanism as PAI-1, while lysine analogs, such as 6-aminocaproic acid and TXA, block the lysine-binding sites on plasminogen, thereby preventing the activation of plasmin and fibrin clot-degradation (19). The USA Food and Drug Administration has removed aprotinin, a bovine product, from the market due to statistical associations with renal failure, cerebrovascular events and mortality, without significantly stronger antifibrinolytic effects over other medications within the class (23–25). As a natural constituent of blood, VLHL PAI-1 may be free of side effects in addition to being an efficient antifibrinolytic agent.

Using a number of in vitro, ex vivo and in vivo models, previous studies have shown that VLHL PAI-1 is able to reduce clot lysis and bleeding in animal experiments (12–14,17). However, the efficacy of this protein had not been compared with other antifibrinolytics. The present study showed that VLHL PAI-1 is a more effective blood clot-protector than 6-aminocaproic acid. Racanelli et al compared recombinant wild PAI-1 to 6-aminocaproic acid in a rabbit model and found that the molar ED50 (effective dose for 50% of population base) was 25,000 times higher for 6-aminocaproic acid than for PAI-1. It was also found that complete inhibition of blood loss was achieved with PAI-1, but the highest dose of 6-aminocaproic acid did not completely inhibit blood loss (26). This outcome supports the conclusions of the present study. However, the absence of platelets and associated platelet function in reference plasma makes the clot weaker. This lack of thrombocytes in the reference plasma may cause 6-aminocaproic acid to exhibit an ED50 value ∼2,000 times higher than that of VLHL PAI-1.

Notably, an increase in R was observed in ≥12.5 µg VLHL PAI-1 (9.0×10−7 mol/l) cases. This phenomenon may be explained by the interaction of thrombin with PAI-1 and the simultaneous formation of cleaved PAI-1 and thrombin-PAI-1 complexes. The kinetics of this reaction are described by a suicide substrate model with a branched reaction that ends in the inhibitor/enzyme complex, the cleaved inhibitor and free enzyme. Due to the branched pathway, it was proposed that 3 mol PAI-1 was required to completely inhibit 1 mol thrombin (27). Since thrombin, a serine protease, converts soluble fibrinogen into insoluble strands of fibrin indirectly through factor XIII, inhibition of thrombin by excess PAI-1 increases the time required for clot formation.

VLHL PAI-1 may also be implemented as a treatment for PAI-1 deficiency. This condition is caused by a lack of PAI-1, an abnormality in the PAI-1 molecule itself, or defects in the secretory dynamics of PAI-1 in the blood (16,28–31). PAI-1 deficiency, a clinically rare bleeding disorder, is characterized by hyperfibrinolytic hemorrhage in the presence of normal thrombus formation (7,9). Patients experience multiple episodes of uncontrolled bleeding, and in severe cases, require blood product transfusions (16,28–31). The class of medications currently used to treat PAI-1 deficiency are antifibrinolytics, which function by inhibiting the conversion of plasminogen into plasmin (22). There are three primary antifibrinolytics utilized in the clinical treatment of the disease: Aprotinin, 6-aminocaproic acid and TXA, which are not always effective and may exhibit a number of side effects (26). Bleeding occurs due to the unopposed conversion of plasminogen to plasmin by the action of tPA and subsequent fibrinolytic activity. Infusion of VLHL PAI-1, structurally homologous to wild-type PAI-1, may provide prophylactic treatment for these patients and restore them to normal health (12–14,28,30).

In conclusion, the inhibition of tPA by VLHL PAI-1 demonstrates an improved efficacy over 6-aminocaproic acid in managing hemorrhagic events in the general patient population. However, concentrations of >9.0×10−7 mol/l VLHL PAI-1 may delay the initiation and dynamics of clot formation. Therefore, in therapy, VLHL PAI-1 should be used in concentrations <9.0×10−7 mol/l.

 Acknowledgements

This study was supported in part by grants from the Frank Stranahan Endowed Chair and Childrens Miracle Network.

 References AntunAGGleasonSArellanoMEpsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignanciesCancer11937843787201310.1002/cncr.2825323921838 DhirAAntifibrinolytics in cardiac surgeryAnn Card Anaesth16117125201310.4103/0971-9784.10974923545866 JankunJSkrzypczak-JankunEPlasminogen activator inhibitor with very long half-life (VLHL PAI-1) can reduce bleeding in PAI-1-deficient patientsCardiovasc Hematol Disord Drug Targets13144150201323988002 MosessonMWFibrinogen and fibrin structure and functionsJ Thromb Haemost318941904200510.1111/j.1538-7836.2005.01365.x16102057 RauJCBeaulieuLMHuntingtonJAChurchFCSerpins in thrombosis, hemostasis and fibrinolysisJ Thromb Haemost5(Suppl 1)102115200710.1111/j.1538-7836.2007.02516.x17635716 ZorioEGilabert-EstellésJEspañaFRamónLACosínREstellésAFibrinolysis: the key to new pathogenetic mechanismsCurr Med Chem15923929200810.2174/09298670878395545518473800 DellasCLoskutoffDJHistorical analysis of PAI-1 from its discovery to its potential role in cell motility and diseaseThromb Haemost93631640200515841306 Cesarman-MausGHajjarKAMolecular mechanisms of fibrinolysisBr J Haematol129307321200510.1111/j.1365-2141.2005.05444.x15842654 EgelundRSchousboeSLSottrup-JensenLRodenburgKWAndreasenPAType-1 plasminogen-activator inhibitor - conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibilityEur J Biochem248775785199710.1111/j.1432-1033.1997.t01-1-00775.x9342229 JankunJYangJZhengHHanFQAl-SenaidyASkrzypczak-JankunERemarkable extension of PAI-1 half-life surprisingly brings no changes to its structureInt J Mol Med296164201221947232 Chorostowska-WynimkoJSwierczRSkrzypczak-JankunEWojtowiczASelmanSHJankunJA novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesisMol Cancer Ther21928200310.1186/1476-4598-2-1912533669 JankunJAleemAMSelmanSHHighly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysisInt J Mol Med20683687200717912461 JankunJKeckRSelmanSHSkrzypczak-JankunESystemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood lossInt J Mol Med26501504201010.3892/ijmm_0000049120818488 JankunJSelmanSHKeckRWŁysiak-SzydłowskaWSkrzypczak-JankunEVery long half-life plasminogen activator inhibitor type 1 reduces bleeding in a mouse modelBJU Int10514691476201010.1111/j.1464-410X.2009.08962.x19912209 JankunJSkotnickaMŁysiak-SzydłowskaWAl-SenaidyASkrzypczak-JankunEDiverse inhibition of plasminogen activator inhibitor type 1 by theaflavins of black teaInt J Mol Med27525529201110.3892/ijmm.2011.61521308350 JankunJSkrzypczak-JankunEYin and yang of the plasminogen activator inhibitorPol Arch Med Wewn119410417200919694224 JankunJAleemAMStruniawskiRLysiak-SzydłowskaWSelmanSHSkrzypczak-JankunEAccelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-lifePharmacol Rep61673680200910.1016/S1734-1140(09)70119-719815949 MorimotoYYoshiokaAImaiYTakahashiYMinowaHKiritaTHaemostatic management of intraoral bleeding in patients with congenital deficiency of alpha2-plasmin inhibitor or plasminogen activator inhibitor-1Haemophilia10669674200410.1111/j.1365-2516.2004.00914.x15357795 SchulmanSPharmacologic tools to reduce bleeding in surgeryHematology Am Soc Hematol Educ Program2012517521201223233628 MakhijaNSarupriaAKumarChoudhary SDasSLakshmyRKiranUComparison of epsilon aminocaproic acid and tranexamic acid in thoracic aortic surgery: clinical efficacy and safetyJ Cardiothorac Vasc Anesth2712011207201310.1053/j.jvca.2013.04.00324050855 HarropSJJankovaLColesMThe crystal structure of plasminogen activator inhibitor 2 at 2.0 A resolution: implications for serpin functionStructure74354199910.1016/S0969-2126(99)80008-210368272 SharpAMSteinPEPannuNSThe active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesionStructure7111118199910.1016/S0969-2126(99)80018-510368279 FergussonDAHébertPCMazerCDBART Investigators: A comparison of aprotinin and lysine analogues in high-risk cardiac surgeryN Engl J Med35823192331200810.1056/NEJMoa080239518480196 HowellNSenanayakeEFreemantleNPaganoDPutting the record straight on aprotinin as safe and effective: results from a mixed treatment meta-analysis of trials of aprotininJ Thorac Cardiovasc Surg145234240201310.1016/j.jtcvs.2012.07.01822889481 IribarrenJLJimenezJJHernándezDPostoperative bleeding in cardiac surgery: the role of tranexamic acid in patients homozygous for the 5G polymorphism of the plasminogen activator inhibitor-1 geneAnesthesiology108596602200810.1097/ALN.0b013e318167aecc18362590 RacanelliALDiemerMJDobiesACDubinJRReillyTMComparison of recombinant plasminogen activator inhibitor-1 and epsilon amino caproic acid in a hemorrhagic rabbit modelThromb Haemost6769269619921509411 van MeijerMSmildeATansGNesheimMEPannekoekHHorrevoetsAJThe suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparinBlood901874188219979292520 FayWPParkerACCondreyLRShapiroADHuman plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 geneBlood9020420819979207454 JankunJSkrzypczak-JankunEBleeding diathesis is associated with an A15T heterozygous mutation in exon 2 of the plasminogen activator inhibitor type 1Exp Ther Med1575577201010.3892/etm_0000009022993578 MehtaRShapiroADPlasminogen activator inhibitor type 1 deficiencyHaemophilia1412551260200810.1111/j.1365-2516.2008.01834.x19141166 SchleefRRHigginsDLPillemerELevittLJBleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitorJ Clin Invest8317471752198910.1172/JCI1140762496147 GenétGFOstrowskiSRSørensenAMJohanssonPIDetection of tPA-induced hyperfibrinolysis in whole blood by RapidTEG, KaolinTEG, and functional fibrinogenTEG in healthy individualsClin Appl Thromb Hemost18638644201210.1177/107602961143452722297558

Effects of various concentrations of VLHL PAI-1 (circles) and 6AC (squares) on the R, G and LY30 values. IC50 values (half maximal inhibitory concentrations) were calculated from the linear fit of four points for VLHL PAI-1 (IC50=8.8×10−8 mol/l) and the linear fit of five points for 6AC (IC50=1.6×10−4 mol/l). R, reaction time; G, strength of clot; LY30, clot lysis 30 min after the maximum amplitude; 6AC, 6-aminocaproic acid; VLHL PAI-1, very long half life plasminogen activator inhibitor-1.

(A) Reference plasma clotted with kaolin and calcium alone (solid line) and with kaolin, calcium and tissue plasminogen activator (tPA; dotted line). Dotted line shows that the clot was quickly dissolved by tPA-activated plasmin. (B) Reference plasma clotted with kaolin, calcium, tPA and very long half life plasminogen activator inhibitor-1 (VLHL PAI-1) and with kaolin, calcium, tPA and a high concentration of VLHL PAI-1 (dotted line). Solid line shows that the addition of VLHL PAI-1 protected the clot from lysis, while the dotted line shows that increased concentrations of VLHL PAI-1 protected the clot from lysis, but delayed clot formation (reduced time from reaction until a 20-mm clot formed) and reduced the angle of clot formation, indicating decreased fibrin cross-linking (reduced A). A, angle is the rate of clot development indicated by fibrinogen and fibrin cross-linking.

Selected thrombelastography parameters for the control-, VLHL PAI-1- and 6AC-treated reference plasma.

Reagent (µg) R (min) K (min) A (°) MA (mm) LY30 (%) G (kdyn/cm2)
Control
  Reference 8.57±0.45 2.04±0.62 63.7±5.6 26.2±2.2 0.0±0.0 1.77±0.19
  tPA-treated 8.09±0.71 2.30±0.55 63.9±4.7 19.3±2.5 87.5±7.5 1.21±0.19
VLHL PAI-1
  25.0 18.27±4.75 5.80±1.80 35.6±7.4 30.2±1.5 0.0±0.0 2.17±0.11
  12.5 23.75±0.70 8.90±5.37 32.1±13.2 26.9±0.6 0.0±0.0 1.85±0.07
  6.25 9.10±0.45 2.67±1.55 62.0±2.8 26.4±0.6 0.0±0.0 1.82±0.35
  3.12 8.70±0.28 6.05±4.87 65.0±13.1 21.1±1.2 0.0±0.0 1.35±0.07
  0.78 7.05±0.77 2.30±1.55 63.3±7.1 24.8±4.5 32.9±1.3 1.70±0.42
  0.39 8.00±0.98 1.55±0.49 71.2±2.4 22.9±2.1 85.0±2.3 1.50±0.14
  0.19 7.25±0.77 N/A 62.4±4.8 15.6±3.6 91.8±0.5 0.90±0.28
6AC
  36.0 8.20±0.00 2.10±0.42 63.3±8.4 22.8±0.2 0.0±0.0 1.50±0.00
  27.0 8.85±0.91 5.10±2.68 54.3±2.9 21.1±1.4 0.1±0.1 1.35±0.07
  18.0 8.20±0.40 2.10±0.30 67.0±2.8 23.0±2.7 2.4±2.3 1.50±0.26
    9.0 8.00±0.70 1.60±0.28 68.3±3.6 24.0±0.6 35.7±12.7 1.55±0.07
    4.5 8.85±1.20 1.65±0.07 67.3±1.6 24.2±1.1 48.3±1.1 1.60±0.14
  1.12 8.00±0.00 1.80±0.00 70.2±0.0 21.8±0.0 80.7±0.0 1.40±0.00
  0.75 8.55±0.07 2.25±0.07 62.9±2.4 21.4±0.6 87.1±0.3 1.35±0.07

Values are expressed as the mean ± standard deviation. R, reaction time; K, time from reaction until a 20-mm clot formed; A, degree indicating the speed of clot formation; MA, maximum amplitude (maximum dynamic properties of platelet-fibrin interaction and contribution of fibrin to clot strength); G, clot strength (derived from MA); LY30, clot lysis 30 min after MA [detailed descriptions can be found in previous studies (14,17,32)]; VLHL PAI-1, very long half life plasminogen activator inhibitor-1; 6AC, 6-aminocaproic acid.